Description
Gonadorelin is a synthetic decapeptide structurally identical to endogenous gonadotropin-releasing hormone (GnRH) — the hypothalamic neuropeptide that drives the hypothalamic-pituitary-gonadal (HPG) axis. Its sequence (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂) matches the native hormone exactly, including the N-terminal pyroglutamate and C-terminal glycine amide that are both required for GnRH receptor binding. Gonadorelin binds GnRHR on anterior pituitary gonadotroph cells, activating phospholipase C and intracellular calcium mobilization to stimulate LH and FSH release. Its plasma half-life of approximately 2–8 minutes makes it a precise tool for studying pulsatile HPG axis signaling — the same reproductive axis regulation that Kisspeptin probes from the upstream hypothalamic level.
Key Characteristics
- Structurally bioidentical to endogenous GnRH — researchers use it to study GnRH receptor activation and downstream gonadotropin dynamics without introducing structural modifications that would confound receptor binding comparisons with the native hormone
- Pulsatile vs continuous administration produces opposite HPG axis effects — intermittent exposure stimulates LH and FSH release through rhythmic receptor activation and recovery; sustained exposure desensitizes GnRHR and suppresses gonadotropin output, making Gonadorelin a uniquely versatile tool for studying bidirectional HPG axis modulation
- Engages the full HPG signaling cascade from pituitary to gonad — unlike Kisspeptin, which acts upstream on GnRH neurons through GPR54 and probes a different regulatory level of the same axis, Gonadorelin acts directly at the pituitary and is used when the study requires isolating pituitary gonadotroph responsiveness rather than upstream GnRH pulse generation
- GnRHR is expressed in extra-pituitary tissues, including prostate, ovarian, and breast cell lines — this peripheral receptor distribution makes Gonadorelin relevant in cancer biology research models examining direct receptor-mediated antiproliferative signaling, independent of its neuroendocrine axis applications
- Plasma half-life of 2–8 minutes following parenteral administration — the shortest of any reproductive axis compound in this catalog, which demands precise experimental timing but enables fine-grained control over pulse interval and receptor occupancy in research designs
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. Gonadorelin degrades rapidly once reconstituted due to its very short plasma half-life. Reconstitute immediately before use, use within the session, and avoid repeated freeze-thaw cycles.
FAQs
What is Gonadorelin?
Gonadorelin is a synthetic decapeptide identical in sequence to endogenous GnRH. It binds GnRH receptors on anterior pituitary gonadotrophs and stimulates LH and FSH release through a phospholipase C and calcium-mediated signaling cascade. Researchers use it to study HPG axis function, pituitary gonadotroph responsiveness, and pulsatile reproductive hormone signaling in laboratory models.
How does pulsatile administration differ from continuous exposure in research models?
The GnRH receptor desensitizes under sustained ligand exposure — continuous Gonadorelin reduces GnRHR surface expression and suppresses gonadotropin output rather than sustaining it. Pulsatile delivery allows receptor recovery between exposures, maintaining LH and FSH stimulation over time. Researchers designing HPG axis studies select the administration interval as a deliberate experimental variable, since the same compound produces opposing downstream effects depending on the dosing pattern.
How does Gonadorelin differ from Kisspeptin in HPG axis research?
Gonadorelin acts directly at the pituitary by binding GnRHR on gonadotroph cells. Kisspeptin acts upstream — it binds GPR54 on hypothalamic GnRH neurons and regulates GnRH pulse generation before any signal reaches the pituitary. Researchers use Gonadorelin when the study requires isolating pituitary-level responsiveness, and Kisspeptin when the question involves upstream hypothalamic regulation of the pulse-generating system itself.
